1 Dividend Stock Down 30% to Buy and Hold for the Next Decade
Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) saw its fortunes reversed last year. Though the drugmaker had performed well since the beginning of the decade, it encountered issues that sank its stock price, mostly related to one of its biggest growth drivers (more on that below).Regeneron's shares are down by 30% over the trailing-12-month period. However, there are still excellent reasons to invest in this stock for the long run. Here's the rundown.Regeneron's issues in the past year are almost entirely related to Eylea, a medicine for wet age-related macular degeneration, which it co-markets with Bayer. The Eylea franchise -- including a high-dose (HD) formulation that first earned approval in 2023 -- is facing stiff competition, biosimilar and otherwise. The medicine's sales growth has slowed considerably as a result. And it might even get worse for Regeneron since Amgen's Pavblu, a biosimilar version of Eylea, hit the market only six months ago. In the fourth quarter, combined U.S. sales of Eylea and Eylea HD increased by only 2% year over year to $1.5 billion.Continue reading
Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) saw its fortunes reversed last year. Though the drugmaker had performed well since the beginning of the decade, it encountered issues that sank its stock price, mostly related to one of its biggest growth drivers (more on that below).
Regeneron's shares are down by 30% over the trailing-12-month period. However, there are still excellent reasons to invest in this stock for the long run. Here's the rundown.
Regeneron's issues in the past year are almost entirely related to Eylea, a medicine for wet age-related macular degeneration, which it co-markets with Bayer. The Eylea franchise -- including a high-dose (HD) formulation that first earned approval in 2023 -- is facing stiff competition, biosimilar and otherwise. The medicine's sales growth has slowed considerably as a result. And it might even get worse for Regeneron since Amgen's Pavblu, a biosimilar version of Eylea, hit the market only six months ago. In the fourth quarter, combined U.S. sales of Eylea and Eylea HD increased by only 2% year over year to $1.5 billion.
